Ark Health review

Ark publishes a $220/month bundled sermorelin plan and identifies Ark Health LLC as the platform and Beluga Health or affiliates as the clinical network. The price is useful, but the cancellation terms are restrictive: requests must arrive 15 days before the next order, and clinical denial does not itself qualify for a refund except where law requires. The dispensing pharmacy remains a question to settle before paying.

Ark Health LLC operates a telehealth platform; its terms identify Beluga Health, P.A. or affiliated professional entities for clinical care and disclose Bask as a technology platform. Its current menu includes injectable sermorelin. These are attributed business relationships, not independent credential verification or identification of the clinician and pharmacy assigned to a patient.

An online visit collects health history for provider review; additional evaluation depends on the provider rather than an unconditional no-labs rule. The terms exclude Mississippi and make other availability service-specific. Ask which clinician and dispensing pharmacy handle your prescription, what labs are required and what they cost. Free expedited shipping applies to eligible orders; the shipping estimate begins after review, approval and fulfillment, not at signup.

Sermorelin is advertised at $220/month, including online consultation, a personalized care plan, medication if prescribed, follow-up and eligible expedited shipping. Confirm dose, supply, selected full debit and renewal schedule before payment; no dose ladder establishes an unconditional same-price-at-all-doses promise. Cancellations must be received at least 15 days before the next order. The current refund policy generally makes sales final, explicitly including clinical denial and cancellation of an unshipped order, except where law requires otherwise. Stopping medication does not cancel the plan.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Confirm the actual formulation and dispensing pharmacy. On the evidence: sermorelin's effect on the growth-hormone axis is a real, well-described mechanism, but the long-term human outcome data behind it stays thin, and no controlled trial shows it delivers the body-composition or anti-aging results it is marketed for. MIC/B12 injections are a lipotropic formulation with essentially no controlled human outcome evidence for fat loss. Individual results vary.